Clinical trial
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In…
NCT00373256 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00373256 |
|---|---|
| Title | A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer |
| Official title | A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Sunitinib, paclitaxel, bevacizumab |
| Enrollment | 488 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Aug 1, 2011 |
| First posted | Sep 8, 2006 |
| Last update posted | Sep 10, 2012 |
| Countries | Germany, Italy, Spain, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: